Drug Trial Radar · NCT02379572
Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas
Last checked: Nov 20, 2026Latest source record: Oct 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
315
Actual
Start
Jun 2015
Primary completion
Jun 2020
Study completion Jul 1, 2021
Sponsor
- Lead sponsor
- University Hospital TuebingenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 5, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Standard treatment of glioblastomas (GBMs) consists of microsurgical resection followed by concomitant chemoradiation. The extent of resection is one of the most important prognostic factors with significant influence on the survival of patients. State of the art technique to achieve the most radical resection possible in conventional surgery is fluorescence-guidance with 5-aminolevulinic acid (5-ALA). If available, intraoperative MRI (iMRI)-guided tumor resection enables an intraoperative resection control and subsequent continuation of surgery if contrast enhancing tumor remnants are found. Therefore a more radical resection and longer survival of patients might be possible. To date no comparison of these two leading technologies for GBM-surgery is available to identify the best surgical therapy of this fatal disease and to justify significant healthcare-economic differences between both technologies. Goal of this study is to assess the value of iMRI guidance in the resection of GBMs in comparison to conventional 5-ALA microsurgery. Primary endpoint is the number of total resections (no residual contrast enhancement) in the postoperative MRI (T1+CM within 48 hours after surgery) in each group. Secondary endpoints are perioperative clinical data, progression free survival, patients' clinical condition and overall survival. The study design was chosen to be a parallel-group approach to compare iMRI and 5-ALA centers (n=13) to exclude possible bias which might be found by randomizing patients within individual iMRI centers and to have surgeons with the most experience possible in use of each respective technology.
Conditions
- Glioblastoma
Interventions
iMRI-guided surgeryDevice
For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.
5-ALA-guided surgeryDrug
For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete resections in the postoperative MRI (T1+/-CM) within 48 hours after surgeryTime frame: 48 hour
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Department of Neurosurgery, Universitätsklinikum Bonn, Bonn, Germany
Bonn, Germany
Department of Neurosurgery, Universität zu Köln, Köln, Germany
Cologne, Germany
Städtisches Klinikum Dresden Friedrichstadt
Dresden, Germany
Department of Neurosurgery, Heinrich-Heine-Universität Düsseldorf, Düsseldorf
Düsseldorf, Germany
Department of Neurosurgery, Friedrich-Alexander-University Erlangen-Nürnberg
Erlangen, Germany
Department of Neurosurgery, Johann Wolfgang Goethe-University Frankfurt am Main
Frankfurt a.M., Germany
Department of Neurosurgery, Georg-August-Universität Göttingen, Göttingen,
Göttingen, Germany
Department of Neurosurgery, University of Ulm, Hospital Günzburg,
Günzburg, Germany
Asklepios Klinik Hamburg, Klinik für Neurochirurgie
Hamburg, Germany
International Neuroscience Institute Hannover, Hannover, Germany
Hanover, Germany
Department of Neurosurgery, Ruprecht-Karls-University Heidelberg
Heidelberg, Germany
Department of Neurosurgery, University of Schleswig-Holstein, Kiel, Germany
Kiel, Germany
Department of Neurosurgery, Westfälische Wilhelms-Universität Münster, Münster, Germany
Münster, Germany
Department of Neurosurgery, Eberhard Karls University, Tübingen,
Tübingen, Germany
Department of Neurosurgery, Julius-Maximilians-Universität Würzburg
Würzburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.